Published guidance, NICE advice and quality standards | Guidance

Showing 191 to 200 of 797

Sort by

Published guidance, NICE advice and quality standards
Title	Reference number	Published	Last updated
Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy	TA836	26 October 2022	26 October 2022
Pembrolizumab for adjuvant treatment of renal cell carcinoma	TA830	19 October 2022	19 October 2022
Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids	TA832	19 October 2022	19 October 2022
Zanubrutinib for treating Waldenstrom's macroglobulinaemia	TA833	19 October 2022	19 October 2022
Fostamatinib for treating refractory chronic immune thrombocytopenia	TA835	19 October 2022	19 October 2022
SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (terminated appraisal)	TA834	12 October 2022	12 October 2022
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy	TA827	5 October 2022	5 October 2022
Ozanimod for treating moderately to severely active ulcerative colitis	TA828	5 October 2022	5 October 2022
Upadacitinib for treating active ankylosing spondylitis	TA829	30 September 2022	30 September 2022
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer	TA823	28 September 2022	28 September 2022